Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Humans (6)
- Female (4)
- Middle Aged (4)
- Adult (3)
- HIV (3)
-
- Immunity, Innate (3)
- Liver Diseases, Alcoholic (3)
- Male (3)
- Aged (2)
- Antiretroviral therapy (2)
- Chemotherapy (2)
- Interferon Type I (2)
- Lung Cancer (2)
- Lung Neoplasms (2)
- Radiotherapy (2)
- Surgery (2)
- United States (2)
- *Attitude to Health (1)
- *Trust (1)
- *Randomized Controlled Trials as Topic (1)
- *Women's Health (1)
- *Liver Diseases (1)
- *Postoperative Complications (1)
- *Surgical Procedures, Elective (1)
- ADVANCE trial-based analysis (1)
- Acute respiratory infection (1)
- Adaptor Proteins, Signal Transducing (1)
- Adenocarcinoma (1)
- Adolescent (1)
- Age Distribution (1)
Articles 31 - 35 of 35
Full-Text Articles in Medicine and Health Sciences
A Phase Ii Trial Of Arc-Based Hypofractionated Intensity-Modulated Radiotherapy In Localized Prostate Cancer, Michael Lock
A Phase Ii Trial Of Arc-Based Hypofractionated Intensity-Modulated Radiotherapy In Localized Prostate Cancer, Michael Lock
Michael Lock
Abstract PURPOSE: To evaluate acute and late genitourinary (GU) and gastrointestinal (GI) toxicity and biochemical control of hypofractionated, image-guided (fiducial markers or ultrasound guidance), simplified intensity-modulated arc therapy for localized prostate cancer. METHODS AND MATERIALS: This Phase II prospective clinical trial for T1a-2cNXM0 prostate cancer enrolled 66 patients who received 63.2 Gy in 20 fractions over 4 weeks. Fiducial markers were used for image guidance in 30 patients and daily ultrasound for the remainder. Toxicity was scored according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. RESULTS: Median follow-up was 36 months. Acute Phase Grade …
Trends In Hiv-Infected Patients Accessing Antiretroviral Therapy In Kenya, Uganda And Tanzania Between 2002 And 2009, Elvin Geng
Elvin H Geng
No abstract provided.
Correcting Mortality For Loss To Follow-Up: A Nomogram Applied To Antiretroviral Treatment Programmes In Sub-Saharan Africa, Elvin Geng
Elvin H Geng
No abstract provided.
Bucindolol: A Pharmacogenomic Perspective On Its Use In Chronic Heart Failure, Neil Smart
Bucindolol: A Pharmacogenomic Perspective On Its Use In Chronic Heart Failure, Neil Smart
Neil Smart
Bucindolol is a non-selective ß-adrenergic receptor blocker with a-1 blocker properties and mild intrinsic sympatholytic activity. The Beta-Blocker Evaluation of Survival Trial (BEST), which is the largest clinical trial of bucindolol in patients with heart failure, was terminated prematurely and failed to show an overall mortality benefit. However, benefits on cardiac mortality and re-hospitalization rates were observed in the BEST trial. Bucindolol has not shown benefits in African Americans, those with significantly low ejection fraction and those in NYHA class IV heart failure. These observations could be due to the exaggerated sympatholytic response to bucindolol in these sub-groups that may …
Optimal Time On Haart For Prevention Of Mother-To-Child Transmission Of Hiv, Carla J. Chibwesa, Mark J. Giganti, Nande Putta, Namwinga T. Chintu, Jessica Mulindwa, Benjamin J. Dorton, Benjamin H. Chi, Jeffrey S. A. Stringer, Elizabeth M. Stringer